Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension

Meng，Juan1,2; Xiao，Guohui1,2; Zhang，Juanjuan1; He，Xing1; Ou，Min1; Bi，Jing1; Yang，Rongqing1; Di，Wencheng1; Wang，Zhaoqin1; Li，Zigang2; Gao，Hong1; Liu，Lei1; Zhang，Guoliang1,2

2020

angiotensin II type1 receptor blockers angiotensin-converting enzyme inhibitors COVID-19 hypertension Renin-angiotensin system

英语

National Natural Science Foundation of China[81873958];National Natural Science Foundation of China[81873958];National Natural Science Foundation of China[81873958];

The dysfunction of the renin-angiotensin system (RAS) has been observed in coronavirus infection disease (COVID-19) patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs), are associated with clinical outcomes remains unknown. COVID-19 patients with hypertension were enrolled to evaluate the effect of RAS inhibitors. We observed that patients receiving ACEI or ARB therapy had a lower rate of severe diseases and a trend toward a lower level of IL-6 in peripheral blood. In addition, ACEI or ARB therapy increased CD3 and CD8 T cell counts in peripheral blood and decreased the peak viral load compared to other antihypertensive drugs. This evidence supports the benefit of using ACEIs or ARBs to potentially contribute to the improvement of clinical outcomes of COVID-19 patients with hypertension.

10.1080/22221751.2020.1746200

Emerging Microbes and Infections

9

1

757-760

SCI

第一 ; 通讯

2-s2.0-85082791338

Scopus

WOS:000524273300001

2222-1751

ESI高被引

1.National Clinical Research Center for Infectious Diseases,Shenzhen Third People's Hospital,Southern University of Science and Technology,Shenzhen,China
2.Shenzhen Bay Laboratory,Shenzhen,China

Meng，Juan,Xiao，Guohui,Zhang，Juanjuan,et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. 2020-01-01.